SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Owens RJ, Young RJ. The genetic engineering of monoclonal antibodies. J Immunol Methods. 1994; 168: 149165.
  • 2
    Shitara K, Kuwana Y, Nakamura K, et al. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced tumor activities. Cancer Immunol Immunother. 1993; 36: 373380.
  • 3
    LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989; 86: 42204224.
  • 4
    Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995; 55: 31403148.
  • 5
    Hoffman T, Hafner D, Ballo H, Haas I, Bier H. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 1997; 17: 44194426.
  • 6
    Bier H, Reiffen KA, Haas I, Stasiecki P. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 1995; 252: 433439.
  • 7
    Modjtahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumour localization of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer. 1996; 73: 228235.
  • 8
    Yang X-D, Jia XC, Corvalan JR, Wang P, Jakobovits A, Davis CG. Potent anti-tumor activity of ABX-EGF, a fully human monoclonal antibody to epidermal growth factor receptor [abstract]. Proc Am Soc Clin Oncol. 1999;18:457a.
  • 9
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogenes. Science. 1987; 234: 177182.
  • 10
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707712.
  • 11
    Press MF, Bernstein L, Thomas PA, et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997; 15: 28942904.
  • 12
    Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P, and the South Australian Breast Cancer Study Group. Clinical significance of HER-2/neu oncogenes amplification in primary breast cancer. J Clin Oncol. 1993;11: 19361942.
  • 13
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p158HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996,14: 737744.
  • 14
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9): 26392648.
  • 15
    Shin DM, Donato NJ, Perez-Solar R, et al. Epidermal growth factor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. AACR 2001; 7: 12041213.
  • 16
    Bonner JA, Ezekiel MP, Robert F, Meredit RF, Spencer SA, Waksal HW. Continued response following treatment with IMC-C225, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb), combined with radiation therapy (RT) in advanced head and neck malignancies [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 5F.
  • 17
    Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 1987; 56: 881914.
  • 18
    Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990; 265: 77097712.
  • 19
    Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with Neu oncogenes. Science. 1985; 230: 11321139.
  • 20
    Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992; 4: 124.
  • 21
    Goldman T, Ben Levy R, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry. 1990; 29: 1102411028.
  • 22
    Wada T, Qian X, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990; 61: 13391347.
  • 23
    Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183232.
  • 24
    Chu CT, Everiss KD, Wikstrand CJ, Batras SK, Kung H-J, Bigner DD. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor (EGFRvIII). Biochem J. 1997; 324: 855861.
  • 25
    Olapade-Olaopa EO, Moscatello DK, MacKay EH, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 2000; 82: 186194.
  • 26
    Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997; 57: 41304140.
  • 27
    Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991; 47(1): 8798.
  • 28
    Thompson DM, Gill GN. The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv. 1985; 4: 767788.
  • 29
    Schlessinger J. The epidermal growth factor receptor as a multi-functional allosteric protein. Biochemistry. 1988; 27: 31193123.
  • 30
    Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997; 57: 48384848.
  • 31
    Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979; 48: 193216.
  • 32
    Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988; 57: 443478.
  • 33
    Yarden Y, Sliwkoski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127136.
  • 34
    Prewett M, Rockwell P, Rose C, et al. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int J Oncol. 1996; 9: 217224.
  • 35
    Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer. 2000; 89(1): 7482.
  • 36
    Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59: 19351940.
  • 37
    Trummell HQ, Raisch KP, Ahmed A, Bonner JA. The biological effects of anti-epidermal growth factor receptor and ionizing radiation in human head and neck tumor cell lines [abstract]. Proc Am Assoc Cancer Res. 1999; 40: 958.
  • 38
    Perry JE, Grossmann ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate. 1998; 35: 117124.
  • 39
    Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13: 1501–-1512.
  • 40
    Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997; 110: 113121.
  • 41
    Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. J Pathol. 1996; 179: 232237.
  • 42
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146: 10291039.
  • 43
    Gille J, Swerlick RA, Caughman SW. Transforming growth factor–α–induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997; 16: 750759.
  • 44
    De Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol. 1998;184: 5357.
  • 45
    Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer. 1996; 32A: 19771982.
  • 46
    Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro. Int J Cancer. 1993; 53: 209214.
  • 47
    Shibata T, Kawano T, Nagayasu H, et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumor Biol. 1996; 17: 168175.
  • 48
    Xie H, Turner T, Wang M-H, Singh RK, Siegal GP, Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor–mediated signals. Clin Exp Metastasis. 1995; 13: 407419.
  • 49
    Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer. 1997; 70: 722726.
  • 50
    Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 1991; 9: 553562.
  • 51
    Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G. Modulation of pro-epidermal growth factor, pro-transforming growth factor α and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res. 1990; 50: 39343939.
  • 52
    Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 1988; 48: 67536757.
  • 53
    Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-α, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998; 37: 285289.
  • 54
    Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor–α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996; 78: 12841292.
  • 55
    Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis. Cancer Res. 1994; 54: 31533159.
  • 56
    Uegaki K, Nio Y, Inoue Y, et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997; 17: 38413848.
  • 57
    Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non–small cell lung cancer. Eur J Cancer. 1996; 32: 20702074.
  • 58
    Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in respectable non–small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997; 3: 515522.
  • 59
    Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor–related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non–small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998; 4: 241249.
  • 60
    Klijn JG, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13: 317.
  • 61
    Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999; 53: 167176.
  • 62
    Beckmann MW, Niederacher D, Massenkeil G, et al. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology. 1996; 53: 441447.
  • 63
    Bucci B, D'Agnano I, Botti C, et al. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res. 1997; 17: 769774.
  • 64
    Yoshida K, Hosoya Y, Sumi S, et al. Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand binding assay. Oncology. 1997; 54: 220225.
  • 65
    Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 1997; 17: 613620.
  • 66
    Bartlett JMS, Langdon SP, Simpson BJB, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996; 73: 301306.
  • 67
    Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Biernat W, Liberski PP. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Pol J Pathol. 1998; 49: 145149.
  • 68
    Ekstrand AJ, James CD, Cavanee WK, Seliger B, Petersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991; 51: 21642172.
  • 69
    Chow N-H, Liu H-S, Lee EI, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997; 17: 12931296.
  • 70
    Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993; 71: 24542460.
  • 71
    Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 824832.
  • 72
    Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996; 74: 12531257.
  • 73
    Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 13: 565570.
  • 74
    Veale D, Kerr N, Gibson G, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non–small cell lung cancer to long term survival. Br J Cancer. 1993; 68: 162165.
  • 75
    Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 1998; 77: 663669.
  • 76
    Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993; 13: 11331137.
  • 77
    Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WLJ, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat. 1994; 29: 7383.
  • 78
    Niikura H, Sasano H, Sato S, Yajima A. Expression of epidermal growth factor–related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol. 1997; 16: 6068.
  • 79
    Turkeri LN, Erton ML, Cevik I, Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology. 1998; 51: 645649.
  • 80
    Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990; 65: 16191625.
  • 81
    Anzai H, Kitadai Y, Bucana CD, Sanchez R, Omoto R, Fidler IJ. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer. 1998; 34: 558565.
  • 82
    Koullias GJ, Kouraklis GP, Raftopoulos IS, Davaris PS, Papadopoulos SA, Golematis BC. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J Surg Oncol. 1996; 63: 166171.
  • 83
    Bauknecht T, Runge M, Schwall M, Pfleiderer A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol. 1988; 29: 147157.
  • 84
    Osaki A, Toi M, Yamanda H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg. 1992; 164: 323326.
  • 85
    Shimizu N, Wang Y, Minoshima S, Ishitoya J. Detection of epidermal growth factor receptor gene amplification in human squamous cell carcinomas using fluorescence in situ hybridization. Jpn J Cancer Res. 1994; 85: 567571.
  • 86
    Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol. 1996; 148: 10471053.
  • 87
    Collins VP. Gene amplification in human gliomas. Glia. 1995; 15: 289296.
  • 88
    Radinsky R, Risin S, Fan Z, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res. 1995; 1: 1931.
  • 89
    Ke LD, Adler-Storthz K, Clayman GL, Yung AWK, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck. 1998; 20: 320327.
  • 90
    Lofts FJ, Gullick WJ. C-erbB2 amplification and overexpression in human tumors. In: DicksonRB, LippmanME, editors. Genes, oncogenes, and hormones: advances in cellular and molecular biology of breast cancer. Boston: Kluwer Academic Publishers, 1991: 161179.
  • 91
    Gorgoulis VG, Barbatis C, Poulias I, Karameris AM. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol. 1995; 8: 758764.
  • 92
    Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ, and the Lung Cancer Study Group. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. J Cancer Res Clin Oncol 1999;125: 6170.
  • 93
    Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. 1999;274: 1761217618.
  • 94
    Modjahedi H, Affleck K, Stubberfield C, Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol. 1998; 13: 335342.
  • 95
    Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995; 95: 18971905.
  • 96
    Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diammine-dichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993; 53: 46374642.
  • 97
    Karnes WE Jr., Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology. 1998;114: 930939.
  • 98
    He Y, Zeng Q, Drenning SD, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst. 1998; 90: 10801087.
  • 99
    Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 1996; 56: 50795086.
  • 100
    Uckun FM, Narla RK, Jun X, et al. Cytotoxic activity of epidermal growth factor–Genistein against breast cancer cells. Clin Cancer Res. 1998; 4: 901912.
  • 101
    Viloria Petit AM, Rak J, Hung M-C, et al. Neutralizing antibodies against epidermal growth factor and ErB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997; 151: 15231530.
  • 102
    Perrotte P, Matsumoto T, Inoue K, Hicklin DJ. Radinsky R. Dinney CPN. Chimeric monoclonal antibody (Mab) C225 to the epidermal growth factor receptor (EGF-R) antibody inhibits angiogenesis in human transitional cell carcinoma (TCC) [abstract]. Proc Am Assoc Cancer Res. 2000;41: 3372.
  • 103
    Zhou J-R, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK. Inhibition of murine bladder tumorigenesis by soy isoflavone via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res. 1998; 58: 52315238.
  • 104
    Dimitroff CJ, Klohs W, Sharma A, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD 166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999; 17: 121135.
  • 105
    Rosen EM, Goldberg ID. Protein factors which regulate cell motility. In Vitro Cell Dev Biol Anim. 1989; 25: 10791087.
  • 106
    Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin Cancer Res. 1995; 1: 545550.
  • 107
    Van de Vijver J, Kumar R, Mendelsohn J. Ligand-induced activation of A431 cell EGF receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem. 1991; 266: 75037508.
  • 108
    Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Role as anticancer agents. Drugs. 2000;59: 753767.
  • 109
    Ciardiello F, Caputo R, Pomatico G, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa™), and EGFR-selective tyrosine kinase inhibitor. Presented in poster form at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, the Netherlands, November 710, 2000.
  • 110
    Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa™), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR. Presented in poster form at the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, California, April 15, 2000.
  • 111
    Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol. 1996; 14: 31563174.
  • 112
    Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of ZD-1839 (‘Iressa’), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 19: 1301.
  • 113
    Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995; 1: 13111318.
  • 114
    Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor–stimulated tyrosine protein kinase activity. J Biol Chem. 1984; 259: 77557760.
  • 115
    Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS, Gill GN. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma in A431 cells. J Biol Chem. 1984;259: 77617766.
  • 116
    Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983;80: 13371341.
  • 117
    Sato JD, Kawamoto T, Le A, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983;1: 511529.
  • 118
    Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996; 19: 419427.
  • 119
    Divgi CR, Welt C, Kris M, et al. Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991; 83: 97104.
  • 120
    Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000; 6(5): 19361948.
  • 121
    Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induced G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996; 56: 36663669.
  • 122
    Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 1998; 4: 29572966.
  • 123
    Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993; 85: 13271333.
  • 124
    Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999; 5: 909916.
  • 125
    Wen X, Li C, Wu Q-P, et al. Potentiation of antitumor activity of PG-TXL with anti-EGFR monoclonal antibody C225 in MDA-MB-468 human breast cancer xenograft [abstract]. Proc Am Assoc Cancer Res. 2000; 41: 2052.
  • 126
    Lydon NB, Mett H, Mueller M, et al. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor–expressing tumor cells in vitro and in vivo. Int J Cancer. 1998; 76: 154163.
  • 127
    Ciardiello F, Caputo R, Bianco R, et al. Potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (IRESSA), and EGFR-selective tyrosine kinase inhibitor [abstract 3075]. Proc Am Assoc Cancer Res. 2000; 41: 482.
  • 128
    Woodburn JR, Kendrew J, Fennell M, Wakeling AE. ZD1839 (‘IRESSA’), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition [abstract]. Proc Am Assoc Cancer Res. 2000; 41: 2552.
  • 129
    Harari PM, Huang S, Li J. Combining radiation with molecular blockade of the EGF receptor in cancer therapy [abstract]. NCI-EORTC International Conference. Proc Am Assoc Cancer Res 1999;5: 88.
  • 130
    Raben D, Buchsbaum DJ, Gillespie Y, Randall S, Saleh M, Waksal H. Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation [abstract]. Proc Am Assoc Cancer Res. 1999; 40: 1244.
  • 131
    Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000; 6: 701708.
  • 132
    Rao GS, Ethier SP. Potentiation of radiation-induced breast cancer cell death by inhibition of epidermal growth factor family of receptors. Int J Radiat Biol. 1999; 45(Suppl): 162.
  • 133
    Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 267: 14561462.
  • 134
    Sartor C. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol. 2000; 6: 1520.
  • 135
    Ennis BW, Valverius EM, Bates SE, et al. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol. 1989; 3: 18301838.
  • 136
    Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther. 2001; 1: 719732.
  • 137
    Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999; 5(2): 257265.
  • 138
    Raben D, Helfrich B, Chan D, et al. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo [abstract]. Proc Am Soc Clin Oncol 2001; 20: 257a.
  • 139
    Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225.
  • 140
    Ezekiel MP, Bonner JA, Robert F, et al. Phase I trial of chimerized anti-epidermal growth factor receptor (EGFR) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies [abstract]. Proc Am Soc Clin Oncol 1999; 18: 1501.
  • 141
    Zakotnik B, Smid L, Budihna M, et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys. 1998; 41: 11211127.
  • 142
    Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 17981804.
  • 143
    Horiot JC, Bontemps P, van den Bogaert W,et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997; 44: 111121.
  • 144
    Hong WK, Arquette M, Nabell L, Needle MN, Waksal HW, Herbst RS. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 224a.
  • 145
    Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 130a.
  • 146
    Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 3a.
  • 147
    Cohen RB, Falcey JW, Paulter VJ, Fetzer KM, Waksal HW. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 1862.
  • 148
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999; 59(6): 12361243.
  • 149
    Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre J-Y. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996; 32A(4): 636640.